Results 81 to 90 of about 42,251 (222)
European Journal of Haematology, EarlyView.ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese +12 more
wiley +1 more source
The FEBS Journal, EarlyView.Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets +2 more
wiley +1 more source
ClinicoEconomics and Outcomes Research, 2022 Kwanza Price,1 Zhun Cao,2 Craig Lipkin,2 Deb Profant,1 Scott Robinson2 1Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Premier Inc., Charlotte, NC, USACorrespondence: Deb ProfantJazz Pharmaceuticals, 3170 Porter Dr., Palo Alto, CA, 94304, USATel/Fax +1 971 ...
Price K +4 more
doaj
scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions
Journal of the European Academy of Dermatology and Venereology, EarlyView.CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu +13 more
wiley +1 more source
Oral Diseases, EarlyView.ABSTRACT Objective Oral complications may negatively influence outcomes of haematopoietic cell transplantation (HCT). A comprehensive view of oral symptoms and symptom burden post‐HCT is lacking. This study aimed to determine the prevalence, severity, and temporal relationships of oral symptoms and their impact on well‐being in the early post‐HCT phase.
Kristina Skallsjö +14 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 10, Page 2674-2683, 15 May 2026.What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang +5 more
wiley +1 more source
Leukemia cutis as the first manifestation of acute myeloid leukemia
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Florian Winkler +5 more
wiley +1 more source
The hidden regulators: Non‐coding RNAs in KMT2A‐rearranged acute lymphoblastic leukemia
International Journal of Cancer, Volume 158, Issue 8, Page 2003-2012, 15 April 2026.Abstract Acute lymphoblastic leukemia (ALL) driven by KMT2A rearrangements (KMT2A‐r) is an aggressive hematologic malignancy with poor prognosis and a high incidence in infants. While KMT2A fusion proteins drive leukemogenesis through transcriptional dysregulation, recent discoveries have highlighted the pivotal role of non‐coding RNAs (ncRNAs) in ...
Maria Augusta Poersch +5 more
wiley +1 more source
Developmental Disorders in Children Recently Diagnosed With Cancer
Pediatric Blood &Cancer, Volume 73, Issue 4, April 2026.ABSTRACT Neurocognitive deficits in adult survivors of childhood cancer are well established, but less is known about developmental disorders (DD) arising shortly after cancer diagnosis. Using 2016–2019 linked Ohio cancer registry and Medicaid data, we compared DD among 324 children with cancer and 606,913 cancer‐free controls.
Jamie Shoag +5 more
wiley +1 more source
2026 Update on the Management of Diffuse Large B‐Cell Lymphoma
American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong +2 more
wiley +1 more source